Introduction
In the development of quinolones, from nalidixic acid to the latest extended-spectrum fluoroquinolones, structural modifications have allowed significant improvements of their properties. The fluoroquinolones developed after norfloxacin, exemplified by ciprofloxacin, had good activity against Gram-negative species and a number of atypical pathogens, good-to-moderate activity against Grampositive species, and were well absorbed and distributed. The growth in understanding of structure-activity relationships of fluoroquinolones has enabled the development of even better compounds. In recent years, interest has focused on improvements in pharmacokinetic properties, greater activity against Gram-positive cocci and anaerobes, activity against fluoroquinolone-resistant strains and improvements in activity against non-fermentative Gramnegative species. The compounds developed in recent years have fulfilled some, but not all, of these goals. 1 On the basis of their in vitro activity, newer fluoroquinolones such as gatifloxacin, clinafloxacin, moxifloxacin and gemifloxacin provide a potentially important breakthrough in chemotherapy against Gram-positive bacteria.
1,2 These fluoroquinolones have either been introduced recently into clinical use or reached the stage of clinical evaluation. Nevertheless, some of them are not quite as active as ciprofloxacin against Enterobacteriaceae, and show no substantial improvements in activity against non-fermentative species. 1 The N-sulfanilylpiperazinyl fluoroquinolones, NSFQ-104 and NSFQ-105, are a novel class of antibacterial fluoroquinolones, structurally related to norfloxacin and ciprofloxacin, respectively. 3 NSFQs have a 4-amino benzenosulphonylamide group attached to the C 7 piperazinyl ring of norfloxacin or ciprofloxacin and display significantly enhanced activity against Staphylococcus aureus. Later, different p-substitutions introduced in the benzenesulphonylamide group of NSFQs yielded a series of 16 new benzenesulphonamide fluoroquinolones (BSFQs). [5] [6] [7] In this study, we compared the in vitro antibacterial activity of several BSFQs with that of NSFQ-105 and ciprofloxacin ( Figure 1 ) against medically significant Grampositive strains such as S. aureus, Streptococcus pneumoniae and Enterococcus faecalis because Gram-positive bacteria are rapidly becoming the most important pathogens in hospital infections, 1 adding new data to our earlier study. 4 
Susceptibility tests
The in vitro activity was assayed by the agar dilution technique as recommended by the NCCLS, 8 using MuellerHinton agar (Merck Química Argentina SAIC, Buenos Aires, Argentina). NSFQ-105 and BSFQs I-III were synthesized in our laboratory as described previously. 3, 5, 7 Ciprofloxacin was obtained from Amifarma (Madrid, Spain). The effect of pH on activity was determined against S. aureus ATCC 29213 by the macrodilution tube method with Mueller-Hinton broth as reported previously. 4 The final inoculum size was 5 ϫ 10 5 cfu/mL.
Results and discussion
The MICs of all newly tested compounds were increased for ciprofloxacin-resistant staphylococci and enterococci. However, NSFQ-105 and BSFQ-I yielded MICs of р1 mg/L and р2 mg/L, against ciprofloxacin-resistant MRSA or methicillin-resistant S. epidermidis (MRSE) and E. faecalis, respectively.
The Table also BSFQ-III was less active than the other BSFQs against Staphylococcus spp. Nevertheless, its MICs were р0.25 mg/L for all quinolone-susceptible staphylococci, which means that BSFQ-III was two-to eight-fold more active than ciprofloxacin. However, BSFQ-III MICs rose to values similar to those of ciprofloxacin against quinolone-resistant isolates. Furthermore, BSFQ-III did not show good anti-pneumococcal activity.
The antibacterial activities of NSFQ-105 and other BSFQs against staphylococci were affected similarly by changes in the pH of Mueller-Hinton broth between 8.5 and 5.5. All BSFQs were four-to eight-fold more active at pH 5.5 than at pH 7.4. In addition, the activities were reduced by shifting the pH from 7.4 to 8.5 (data not shown). Previously, we had related such behaviour to the high proportion of the uncharged form of the NSFQs at pH 5.5. 4, 6 It is also documented that the activity of zwitterionic fluoroquinolones drops in acidic media. 11 Hence, NSFQ-105 and BSFQ-I were 128-fold more active than ciprofloxacin at pH 5.5. This observation may have clinical relevance for the use of the new derivatives at sites of infection such as macrophages, abscesses or the urinary tract.
In order to compare the activity of the test compounds, log MICs of each were correlated with those of ciprofloxacin. High degrees of correlation between quinolone log MICs have been reported previously for other fluoroquinolones, with slopes of regression close to unity and regression coefficients usually Ͼ0.85.
12 Figure 2 shows a plot of BSFQ-I log MIC versus ciprofloxacin log MIC for 91 Staphylococcus spp., including MSSA, MRSA and coagulase-negative staphylococci. Such a plot reveals a bimodal distribution of the strains assayed; a linear regression analysis shows a slope of 1.05 with r 2 ϭ 0.89. Similar distributions and linear correlations were also observed for NSFQ-105, BSFQ-II and BSFQ-III. The same behaviour was observed for E. faecalis but not for pneumococci. These results indicate cross-resistance between new BSFQs and ciprofloxacin in S. aureus, S. epidermidis and E. faecalis, but not in pneumococci. Previously, we have shown that the primary target of NSFQ-105 and other BSFQs in pneumococci is DNA gyrase rather than topoisomerase IV (the primary target for ciprofloxacin in pneumococci). 10 This observation, together with the present results, could indicate a different target affinity in pneumococci compared with the other bacteria.
In conclusion, the BSFQs, a group of new fluoroquinolones that exhibit in vitro activity against Grampositive bacteria that is comparable to or better than other quinolones under investigation or recently introduced into clinical use, have been developed. Our results show that of the new BSFQs, NSFQ-105 and BSFQ-I exhibited the lowest MICs for most of the organisms tested, including ciprofloxacin-resistant strains. Although BSFQ-II also displays potent antibacterial activity, it is less active than NSFQ-105 or BSFQ-I against ciprofloxacin-resistant clinical isolates. On the other hand, a structure-activity study with the BSFQs showed BSFQ-II as an outlier. 
